Tag Archive for: Cancer

iOnctura announces FDA clearance of IND application for roginolisib, a first-in-class allosteric modulator of PI3Kδ

/in

Roginolisib is in development for solid and hematologic malignancies including uveal melanoma Geneva, Switzerland and Amsterdam, The Netherlands, 31 October 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that the US Food and Drug Administration (FDA) has granted permission to proceed […]

Read more

New Research Highlights Potential of iOnctura Strategy Combining Autotaxin and TGF-Β Inhibitors In Cancer

/in

Amsterdam, The Netherlands and Geneva, Switzerland, 19 October 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces publication of new research data in the peer-reviewed journal Cancer Research, that supports a strategy of combining autotaxin inhibitor IOA-289 with TGF-β pathway inhibitor IOA-359. Read […]

Read more

4SC receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL in the European Union

/in

The European Medicines Agency (EMA) has granted Orphan Drug Designation for resminostat for treatment of cutaneous T-cell lymphoma (CTCL) ODD benefits include 10 years’ market exclusivity in the European Union The Marketing Authorisation Application (MAA) for Kinselby (resminostat) in the EU remains on track for filing in Q1 2024 Planegg-Martinsried, Germany, 18 October 2023 – 4SC […]

Read more

Ariceum Therapeutics’ targeted radiopharmaceutical 177Lu-satoreotide exhibits promising clinical response and good tolerability profile in patients with advanced neuroendocrine tumours

/in

95% of patients (36 of 38) treated with Ariceum’s radiopharmaceutical satoreotide achieved disease control in Phase I/II trial That included 21% of patients (8 of 38) who experienced tumour reduction The study, just published in the European Journal of Nuclear Medicine and Molecular Imaging, concluded the treatment “has an acceptable safety profile with a promising […]

Read more

HERVOLUTION Therapeutics appoints Moderna Co-Founder and MIT Professor Robert S. Langer as Chair of its Scientific Advisory Board

/in

Prof Langer is a world-renowned scientist and entrepreneur who was a driving force behind Moderna’s mRNA nanoparticle Covid vaccine • Prof Langer has joined HERVOLUTION to develop HERVs that are a novel untapped target in oncology and senescence related diseases • Prof Langer’s scientific knowledge and entrepreneurial expertise will help expedite HERVOLUTION’s lead candidate into clinical development […]

Read more
© Optimum Strategic Communications.